Discover best-in-market prices on clinically preferred products―together with a suite of applications supporting pharmacy operations and analytics, and innovative strategies to address industry initiatives and issues.

HealthTrust Presents 2017 Member Recognition Awards

LAS VEGAS, Nevada—July 18, 2017—HealthTrust has recognized 21 individuals with its highest honor during the 2017 HealthTrust University Conference in Las Vegas. The healthcare performance improvement company established its annual Member Recognition Award program to acknowledge outstanding contributions of member organizations for demonstrating best practices and achieving operational excellence benefitting providers and their patients. Awards […]

Read More

Pills and money

The 340B Drug Pricing Program

The 340B Drug Pricing Program requires drug manufacturers participating in Medicaid to provide outpatient drugs at significantly reduced prices to eligible healthcare organizations or covered entities, such as safety-net hospitals. This program was originally set up in 1992 to provide support to safety-net hospitals that take care of a large number of the poor and […]

Read More

Latest ICER Report Looks at the Value of Drugs for Rheumatoid Arthritis

Rheumatoid arthritis (RA) is the latest high-profile disease for which the Institute for Clinical and Economic Review (ICER) has constructed a “value framework” for assessing and comparing available drug treatments. In April, ICER issued a comprehensive, 529-page report on targeted immune modulators (TIMs) for RA that covers 14 medicines—all but two biologics, and none biosimilars. […]

Read More

Prioritizing Antimicrobial Stewardship

In 2014, California became the first state to require acute care hospitals to implement antimicrobial stewardship programs in their facilities. Nearly three years later, it remains the only state in the nation with such a law—but that is set to change. In June 2016, the Centers for Medicare & Medicaid Services (CMS) announced proposed changes […]

Read More

Pharmaceutical M&A: A New Kind of Drug Deal

As more drug companies merge and overtake each other, healthcare facilities and pharmaceutical customers are feeling the squeeze. With fewer companies in the marketplace, competition is limited, driving higher prices and drug scarcity.

Read More

Biosimilars Update: Zarxio

In March 2015, the FDA green-lighted Zarxio, the first biosimilar product to be approved in the United States, signaling some relief from rising drug costs.

Read More

HealthTrust Addressing Pharmacy Leadership Shortage With Unique Residency Program

In 2014, HealthTrust established the nation’s first corporate-based training program for future pharmacy leaders that provides early career exposure to critical business functions, value-based purchasing and the economic realities of modern medicine, including better management of limited healthcare resources.

Read More

Five Drivers of Rising Drug Costs

Supplier consolidation, heightened FDA scrutiny, industry profit-taking and recurring shortages are conspiring to inflate prices on older drugs.

Read More